Lemtrada ‘a permanent therapy’ claims doctor

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Lemtrada ‘a permanent therapy’ claims doctor

Postby MSUK » Mon Jun 01, 2015 5:27 am

Speaking at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis, Indiana, Mr Samuel F. Hunter, MD, PhD, president of the Advanced Neurosciences Institute in Franklin, Tennessee, gave a presentation on outcomes in patients with relapsing multiple sclerosis (MS) treated with Lemtrada (alemtuzumab)......... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2876
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: Lemtrada ‘a permanent therapy’ claims doctor

Postby CureOrBust » Mon Jun 01, 2015 5:27 pm

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a.
Can someone explain to me the difference between "slowing disability progression" and "accumulation of disability"? :? How can one reach statistical significance and the other not?
User avatar
CureOrBust
Family Elder
 
Posts: 3341
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Lemtrada ‘a permanent therapy’ claims doctor

Postby Anunymouse » Mon Oct 12, 2015 8:39 pm

I'm still trying to figure out why aubagio claims that begin 7% better than placebo is "significant".
Anunymouse
Family Member
 
Posts: 54
Joined: Thu Sep 04, 2014 10:07 pm

Re: Lemtrada ‘a permanent therapy’ claims doctor

Postby NHE » Mon Oct 12, 2015 9:58 pm

CureOrBust wrote:
In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a.
Can someone explain to me the difference between "slowing disability progression" and "accumulation of disability"? :? How can one reach statistical significance and the other not?

They are discussing two different studies, CARE-MS I and CARE-MS II.
User avatar
NHE
Volunteer Moderator
 
Posts: 4563
Joined: Sat Nov 20, 2004 3:00 pm

Re: Lemtrada ‘a permanent therapy’ claims doctor

Postby CureOrBust » Tue Oct 13, 2015 12:40 am

Ah, that learn me for skim reading.
User avatar
CureOrBust
Family Elder
 
Posts: 3341
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia


Return to Campath (Lemtrada, Alemtuzumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service